European Medicines Agency reviews new coronavirus drug
The European Medicines Agency (EMA) has started the review process for a new coronavirus drug.
The EMA announced on Thursday that the Swedish-British manufacturer AstraZeneca has developed the combination drug Evusheld, which is intended to prevent Covid-19 in adults.
The Agency stated that the initial test results indicated that the drug is effective in protecting against the disease.
“The experts are now continuously evaluating data from tests and weighing up the advantages and disadvantages of the drug.
“It is not known when a final result will be available.”
According to the authority, the manufacturer has not yet applied for approval for the European market.
The drug consists of the active ingredients tixagevimab and cilgavimab.
So far, only the drug remdesivir has been approved in the EU as a special coronavirus drug.
Meanwhile, approval procedures are on the way for five preparations.
A total of three drugs are currently still being examined by the experts.(dpa/NAN)
